171 related articles for article (PubMed ID: 27146584)
1. Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1.
Speyer CL; Nassar MA; Hachem AH; Bukhsh MA; Jafry WS; Khansa RM; Gorski DH
Breast Cancer Res Treat; 2016 Jun; 157(2):217-228. PubMed ID: 27146584
[TBL] [Abstract][Full Text] [Related]
2. Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer.
Speyer CL; Smith JS; Banda M; DeVries JA; Mekani T; Gorski DH
Breast Cancer Res Treat; 2012 Apr; 132(2):565-73. PubMed ID: 21681448
[TBL] [Abstract][Full Text] [Related]
3. Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells.
Dolfi SC; Medina DJ; Kareddula A; Paratala B; Rose A; Dhami J; Chen S; Ganesan S; Mackay G; Vazquez A; Hirshfield KM
Oncotarget; 2017 Jul; 8(27):44639-44653. PubMed ID: 28591718
[TBL] [Abstract][Full Text] [Related]
4. The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells.
Le MN; Chan JL; Rosenberg SA; Nabatian AS; Merrigan KT; Cohen-Solal KA; Goydos JS
J Invest Dermatol; 2010 Sep; 130(9):2240-9. PubMed ID: 20505744
[TBL] [Abstract][Full Text] [Related]
5. Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer.
Banda M; Speyer CL; Semma SN; Osuala KO; Kounalakis N; Torres Torres KE; Barnard NJ; Kim HJ; Sloane BF; Miller FR; Goydos JS; Gorski DH
PLoS One; 2014; 9(1):e81126. PubMed ID: 24404125
[TBL] [Abstract][Full Text] [Related]
6. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
[TBL] [Abstract][Full Text] [Related]
7. Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells.
Teh JL; Shah R; La Cava S; Dolfi SC; Mehta MS; Kongara S; Price S; Ganesan S; Reuhl KR; Hirshfield KM; Karantza V; Chen S
Breast Cancer Res Treat; 2015 May; 151(1):57-73. PubMed ID: 25859923
[TBL] [Abstract][Full Text] [Related]
8. Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer.
Sexton RE; Hachem AH; Assi AA; Bukhsh MA; Gorski DH; Speyer CL
Sci Rep; 2018 Oct; 8(1):16008. PubMed ID: 30375476
[TBL] [Abstract][Full Text] [Related]
9. Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma.
Namkoong J; Shin SS; Lee HJ; Marín YE; Wall BA; Goydos JS; Chen S
Cancer Res; 2007 Mar; 67(5):2298-305. PubMed ID: 17332361
[TBL] [Abstract][Full Text] [Related]
10. Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1
Shah R; Singh SJ; Eddy K; Filipp FV; Chen S
Cancer Res; 2019 Apr; 79(8):1799-1809. PubMed ID: 30987979
[TBL] [Abstract][Full Text] [Related]
11. Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
Lee HJ; Wall BA; Wangari-Talbot J; Shin SS; Rosenberg S; Chan JL; Namkoong J; Goydos JS; Chen S
Clin Cancer Res; 2011 Nov; 17(22):7080-92. PubMed ID: 21844014
[TBL] [Abstract][Full Text] [Related]
12. Tryptophan hydroxylase 1 and 5-HT
Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
[TBL] [Abstract][Full Text] [Related]
13. Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells.
Martino JJ; Wall BA; Mastrantoni E; Wilimczyk BJ; La Cava SN; Degenhardt K; White E; Chen S
Oncogene; 2013 Sep; 32(37):4366-76. PubMed ID: 23085756
[TBL] [Abstract][Full Text] [Related]
14. Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells.
Wall BA; Wangari-Talbot J; Shin SS; Schiff D; Sierra J; Yu LJ; Khan A; Haffty B; Goydos JS; Chen S
Pigment Cell Melanoma Res; 2014 Mar; 27(2):263-74. PubMed ID: 24330389
[TBL] [Abstract][Full Text] [Related]
15. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
16. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
[TBL] [Abstract][Full Text] [Related]
17. Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes.
Mehta MS; Dolfi SC; Bronfenbrener R; Bilal E; Chen C; Moore D; Lin Y; Rahim H; Aisner S; Kersellius RD; Teh J; Chen S; Toppmeyer DL; Medina DJ; Ganesan S; Vazquez A; Hirshfield KM
PLoS One; 2013; 8(7):e69851. PubMed ID: 23922822
[TBL] [Abstract][Full Text] [Related]
18. Riluzole Inhibits Proliferation, Migration and Cell Cycle Progression and Induces Apoptosis in Tumor Cells of Various Origins.
Lemieszek MK; Stepulak A; Sawa-Wejksza K; Czerwonka A; Ikonomidou C; Rzeski W
Anticancer Agents Med Chem; 2018; 18(4):565-572. PubMed ID: 29493465
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library.
Fujita T; Mizukami T; Okawara T; Inoue K; Fujimori M
Breast Cancer; 2014 Nov; 21(6):738-47. PubMed ID: 23456737
[TBL] [Abstract][Full Text] [Related]
20. Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression.
Wen Y; Li J; Koo J; Shin SS; Lin Y; Jeong BS; Mehnert JM; Chen S; Cohen-Sola KA; Goydos JS
Cancer Res; 2014 May; 74(9):2499-509. PubMed ID: 24491800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
